SereNeuro Therapeutics
PrivateLast Round
Grant
May 13, 2025
Total Funding Raised
$5.02M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
SereNeuro Therapeutics operates in Healthcare & Life Sciences and is based in Baltimore, Maryland. Its latest recorded funding round was a Grant round in May 2025.
SereNeuro Therapeutics is a biotechnology company developing non-opioid cell and gene therapies for chronic pain management.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Government Contracts, Revenue Share, Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
SereNeuro Therapeutics Comparables
Compare SereNeuro Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Genascence Corporation | 81% | |
| Mimetic Medicines | 76% | |
| Adolore Biotherapeutics, Inc. | 74% |
For institutional investors. Book with your work email.
SereNeuro Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | May 13, 2025 | ||||
| Seed | Feb 28, 2025 | ||||
| Grant | Nov 20, 2023 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
SereNeuro Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Johns Hopkins Technology Ventures | Grant |
| Maryland Stem Cell Research Fund | Grant |
| Ecphora Capital | Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 25, 2026
Monthly visitors grew 143% MoM, reaching 2.3K.
- May 13, 2025
Received funding from the Maryland Stem Cell Research Fund.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- is_developingOct 6, 2026
SereNeuro Therapeutics, Inc. is developing SN101, an off-the-shelf treatment designed to sequester inflammatory pain factors in arthritic joints without relaying pain signals to the brain; the candidate remains preclinical and is advancing toward manufacturing and work required for an Investigational New Drug application.
- receives_awardOct 5, 2026
In Sep '26, SereNeuro Therapeutics, Inc. received its first NIH Small Business Innovation Research (SBIR) award to support SN102 through the NIH HEAL Initiative, which seeks scientific solutions to the opioid crisis, including non-addictive pain treatments.
- receives_financingOct 2, 2026
SereNeuro Therapeutics, Inc. receives $400K in commercialization financing to help develop human stem cell-based products in Maryland.
For institutional investors. Book with your work email.
SereNeuro Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about SereNeuro Therapeutics's valuation, stock price, and market status.
Is SereNeuro Therapeutics a public or private company?
SereNeuro Therapeutics is a private company.
What is the current stock price of SereNeuro Therapeutics?
SereNeuro Therapeutics is a private company, so its shares have no public market price. Caplight tracks SereNeuro Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is SereNeuro Therapeutics worth (valuation)?
Valuation information for SereNeuro Therapeutics is not publicly available.
Can I buy SereNeuro Therapeutics stock?
SereNeuro Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was SereNeuro Therapeutics's last funding round?
SereNeuro Therapeutics's most recent funding round was Grant on May 13, 2025.
Who are the main investors in SereNeuro Therapeutics?
Key investors in SereNeuro Therapeutics include Johns Hopkins Technology Ventures, Maryland Stem Cell Research Fund, Ecphora Capital.
Will SereNeuro Therapeutics IPO soon?
No public IPO plans have been announced for SereNeuro Therapeutics.
How can I track SereNeuro Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in SereNeuro Therapeutics's shares on secondary markets.